Amyloidosis Clinical Trials

148 recruitingLast updated: June 17, 2026

There are 148 actively recruiting amyloidosis clinical trials across 42 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Boston, Massachusetts, United States, New York, New York, United States, Pavia, Italy. Updated daily from ClinicalTrials.gov.


Amyloidosis Trials at a Glance

148 actively recruiting trials for amyloidosis are listed on ClinicalTrialsFinder across 6 cities in 42 countries. The largest study group is Phase 2 with 26 trials, with the heaviest enrollment activity in Boston, New York, and Pavia. Lead sponsors running amyloidosis studies include Fondazione IRCCS Policlinico San Matteo di Pavia, Alnylam Pharmaceuticals, and Mayo Clinic.

Browse amyloidosis trials by phase

Treatments under study

About Amyloidosis Clinical Trials

Looking for clinical trials for Amyloidosis? There are currently 34 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Amyloidosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Amyloidosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 148 trials

Recruiting
Phase 3

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals1,250 enrolled233 locationsNCT07052903
Recruiting
Phase 3

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

Hereditary Transthyretin-Mediated Amyloidosis With PolyneuropathyhATTR-PN
Alnylam Pharmaceuticals125 enrolled29 locationsNCT07223203
Recruiting
Not Applicable

Concordance for Transthyretin Amyloidosis Between Synovial Biopsy and Anterior Carpal Ligament Biopsy

Transthyretin AmyloidosisCarpal Tunnel
Clinique Saint Jean, France500 enrolled1 locationNCT07644325
Recruiting
Phase 2

A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).

Multiple MyelomaAL Amyloidosis
Shanghai Zhongshan Hospital30 enrolled1 locationNCT07638683
Recruiting
Phase 1

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Relapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) Amyloidosis
Janssen Research & Development, LLC180 enrolled29 locationsNCT05652335
Recruiting

Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis

Cardiac AmyloidosisCardiomyopathy, HypertrophicLumbar Spinal Stenosis+3 more
Columbia University1,663 enrolled6 locationsNCT06034405
Recruiting
Early Phase 1

Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis

AL AmyloidosisSystemic Light Chain AmyloidosisRelapsed/Refractory Light Chain Amyloidosis
Beijing Boren Hospital30 enrolled1 locationNCT07626476
Recruiting
Phase 1

Test-retest Study With [18F]FBB in Cardiac Amyloidosis

Cardiac Amyloidosis
Lantheus Germany GmbH15 enrolled2 locationsNCT06790394
Recruiting

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

PolyneuropathyHereditary Transthyretin-mediated (hATTR) Amyloidosis
Alnylam Pharmaceuticals10 enrolled7 locationsNCT05040373
Recruiting
Not Applicable

Prevalence and Significance of ATTR Aortic Valve Amyloidosis in Degenerative Aortic Stenosis

Amyloidosis
University Hospital, Toulouse100 enrolled1 locationNCT04636684
Recruiting
Phase 1Phase 2

Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)

ATTR Amyloidosis Wild Type
Steen Hvitfeldt Poulsen15 enrolled1 locationNCT06318260
Recruiting

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Transthyretin-Mediated AmyloidosisATTR Amyloidosis
Alnylam Pharmaceuticals1,500 enrolled40 locationsNCT04561518
Recruiting

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Transthyretin AmyloidosisATTR-CMATTRv-PN+3 more
AstraZeneca1,850 enrolled67 locationsNCT06465810
Recruiting

OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

ATTR Amyloidosis
AstraZeneca52,121 enrolled26 locationsNCT06355934
Recruiting
Phase 1

Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load

AmyloidosisCryopyrin-Associated Periodic Syndromes
National Institute of Allergy and Infectious Diseases (NIAID)30 enrolled1 locationNCT06974877
Recruiting
Phase 2

The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

Breast CarcinomaUrothelial CarcinomaOvarian Carcinoma+26 more
Mayo Clinic27 enrolled1 locationNCT07285044
Recruiting
Phase 1Phase 2

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion

Immunoglobulin Light Chain (AL) Amyloidosis
AbbVie76 enrolled23 locationsNCT06158854
Recruiting
Phase 3

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

CardiomyopathiesAmyloidosisHeart Diseases+3 more
Eidos Therapeutics, a BridgeBio company587 enrolled101 locationsNCT06563895
Recruiting
Phase 1Phase 2

Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients

Systemic Light Chain Amyloidosis
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.70 enrolled27 locationsNCT07266116
Recruiting
Not Applicable

Elevated Rate Pacing of Cardiac Amyloidosis

Cardiac AmyloidosisPacemaker
University of Minnesota10 enrolled1 locationNCT07583823